Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy.
Last Updated: Wednesday, October 12, 2022
A retrospective review that examines the clinical characteristics, bone marrow findings, engraftment, and hematopoietic reconstitution of patients who received a stem cell transplantation for a CAR T-cell therapy-related hematologic toxicity, such as cytopenia and sepsis.
Advertisement
News & Literature Highlights